Tiziana Life Sciences reports positive results for nasal MS drug foralumab

Tiziana Life Sciences reported that its intranasal drug foralumab reduced brain inflammation and was safe in a mid-stage trial involving 48 patients with non-active secondary progressive multiple sclerosis. The study found that the 50-microgram dose resulted in a statistically significant reduction in microglial activation compared to placebo after 12 weeks, as measured by PET imaging. Both doses were well tolerated, and participants showed improvements in fatigue scores compared to placebo.

The results from the Phase 2a study indicate that foralumab may reduce neuroinflammation in a form of multiple sclerosis that currently lacks approved treatments. The drug showed a statistically significant reduction in microglial activation at the 50-microgram dose, suggesting potential efficacy in managing the disease.